Corcept Therapeutics CORT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's EPS (diluted)?
- Corcept Therapeutics (CORT) reported EPS (diluted) of -$0.30 in Q1 2026.
- How has Corcept Therapeutics's EPS (diluted) changed year-over-year?
- Corcept Therapeutics's EPS (diluted) decreased by 276.5% year-over-year, from $0.17 to -$0.30.
- What is the long-term trend for Corcept Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Corcept Therapeutics's EPS (diluted) has grown at a -2.0% compound annual growth rate (CAGR), from $0.89 to $0.82.
- What does EPS (diluted) mean?
- The amount of profit per share assuming all potential sources of new shares are converted into actual stock.
- How do you interpret EPS (diluted)?
- Higher values indicate stronger profitability even after accounting for potential dilution. A significant gap between basic and diluted EPS highlights the potential impact of outstanding stock options or convertible instruments.
- How does EPS (diluted) compare across companies?
- Widely used by analysts to compare the 'worst-case' earnings scenario across companies with complex capital structures.